Vitex suspends trial for pathogen inactivation system
This article was originally published in Clinica
VI Technologies (Vitex) has suspended a phase III study of its Inactine blood pathogen inactivation system, after one of the patients in the trial developed an immune response to cells treated with the technology. The company said that pending further evaluation with the US FDA, no additional patients would be recruited to the study. Inactine is designed to inactivate viruses, bacteria and parasites in red blood cells.
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.